BioReference Laboratories Inc. (BRLI, Financial) filed Annual Report for the period ended 2010-10-31.
Bio Refernc Lab has a market cap of $644.1 million; its shares were traded at around $23.64 with a P/E ratio of 24.2 and P/S ratio of 1.4. BRLI is in the portfolios of Manning & Napier Advisors, Inc, Paul Tudor Jones of The Tudor Group, Jim Simons of Renaissance Technologies LLC, Mario Gabelli of GAMCO Investors.
Over the last several years, we have experienced substantial growth and have expanded our operational capabilities. In September 2006, we acquired certain assets and liabilities of two Maryland laboratories, a pathology laboratory and a genetics laboratory for $1,500,000 and $10,000,000, respectively. The genetics laboratory purchase agreement contained certain operational targets, which, if achieved in the four years following the closing, could result in an increase in the purchase price from $10,000,000 to a maximum $17,000,000. During the recently completed fiscal year ended October 31, 2010, as well as for the fiscal years ended October 31, 2009, October 31, 2008 and October 31, 2007, the genetics laboratory achieved these targets, entitling the prior owners to receive $250,000 in cash and an additional 23,096 shares of our Common Stock with respect to the fiscal year ended October 31, 2010, and 23,096 shares of our Common Stock with respect to each of the fiscal years ended October 31, 2009, October 31, 2008 and October 31, 2007, as well as $1,917,000 in cash with respect to the fiscal years ended October 31, 2009, October 31, 2008 and October 31, 2007. These amounts have been accrued and are reflected in our financial statements. We retained the staffs of these laboratories and continue to operate at the same locations. We intend to develop further and expand both our core laboratory business and other products. This growth and expansion has placed, and will continue to place, a significant strain on our resources. We cannot assure that we will be able to successfully manage a continuation of the rate of growth similar to that which we have experienced in the past, should such growth occur.
Read the The complete Report
Bio Refernc Lab has a market cap of $644.1 million; its shares were traded at around $23.64 with a P/E ratio of 24.2 and P/S ratio of 1.4. BRLI is in the portfolios of Manning & Napier Advisors, Inc, Paul Tudor Jones of The Tudor Group, Jim Simons of Renaissance Technologies LLC, Mario Gabelli of GAMCO Investors.
Highlight of Business Operations:
The aggregate market value of the voting stock of Bio-Reference Laboratories, Inc. (consisting of Common Stock, $.01 par value) held by non-affiliates of the registrant was approximately $575,000,000 based upon the last sale price for the Common Stock on April 30, 2010, the last trading date of the registrants most recently completed second quarter, as reported on the NASDAQ Global Market System.Over the last several years, we have experienced substantial growth and have expanded our operational capabilities. In September 2006, we acquired certain assets and liabilities of two Maryland laboratories, a pathology laboratory and a genetics laboratory for $1,500,000 and $10,000,000, respectively. The genetics laboratory purchase agreement contained certain operational targets, which, if achieved in the four years following the closing, could result in an increase in the purchase price from $10,000,000 to a maximum $17,000,000. During the recently completed fiscal year ended October 31, 2010, as well as for the fiscal years ended October 31, 2009, October 31, 2008 and October 31, 2007, the genetics laboratory achieved these targets, entitling the prior owners to receive $250,000 in cash and an additional 23,096 shares of our Common Stock with respect to the fiscal year ended October 31, 2010, and 23,096 shares of our Common Stock with respect to each of the fiscal years ended October 31, 2009, October 31, 2008 and October 31, 2007, as well as $1,917,000 in cash with respect to the fiscal years ended October 31, 2009, October 31, 2008 and October 31, 2007. These amounts have been accrued and are reflected in our financial statements. We retained the staffs of these laboratories and continue to operate at the same locations. We intend to develop further and expand both our core laboratory business and other products. This growth and expansion has placed, and will continue to place, a significant strain on our resources. We cannot assure that we will be able to successfully manage a continuation of the rate of growth similar to that which we have experienced in the past, should such growth occur.
Read the The complete Report
